

Lupin Appoints Abdelaziz Toumi as CEO of its API CDMO Subsidiary

Mumbai, June 17, 2024: Global pharma major Lupin Limited (Lupin) today announced the appointment of Abdelaziz Toumi (Abdel) as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS). LMS is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and is starting to build its Contract Development and Manufacturing Operations (CDMO) business.

Abdel is a seasoned leader with a blend of scientific and commercial skills, and brings over two decades of rich experience in the biotech, pharma and CDMO sectors, spanning Europe, North America and Asia. He has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he was responsible for driving growth, innovation and operational excellence. Abdel will be based in Switzerland and will spend considerable time in India.

Abdel holds a Doctorate in Chemical Engineering and a Master's degree in Business Administration from the University of Southern Queensland.

Commenting on the appointment, **Lupin's Managing Director, Nilesh Gupta** said, "We are delighted to welcome Abdel to our team. He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers."

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.8% of its revenue in research and development in FY24.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on:

Twitter: <https://twitter.com/LupinGlobal>

LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <https://www.facebook.com/LupinWorld/>

**For further information or queries please contact –
Heena Dhedhi**

Deputy General Manager – Corporate Communications

Email: heenadhedhi@lupin.com